For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Vyndamax and Tafamidis meglumine represents a significant breakthrough . These groundbreaking therapies preserve the transthyretin protein, preventing its harmful build-up and allev